An observational study in Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma, sponsored by iOMEDICO AG. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by iOMEDICO AG · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Carcinoma, Hepatocellular with a site in Germany — 23 open to participants now, 38 under way, 9 of them phase 3. Carcinoma, Hepatocellular · Germany.
Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, this one is the 4th largest by planned enrollment of the 25 observational ones that give a count, is one of 7 that started in 2020, is one of 25 observational ones, reaches primary completion later than 11 of the 37 other live ones, and was the 109th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →23 of the 149 studies in Carcinoma, Hepatocellular with a site in Germany are open now. Recruiting first, the newest first:
AIO-Studien-gGmbH · Sites in Germany
Ages 18+
RWTH Aachen University · Sites in Germany
Ages 18–80
CatalYm GmbH · Sites in Germany, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Germany, United States, Australia and 11 more countries
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 59 · Phase 3 37 · Phase 4 4
First in 1999; this study’s year is marked. 7 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 128 across the 124 interventional studies, 250 across the 25 observational. Of the 101 that completed or were terminated, 43 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 149 have an industry lead sponsor. The 10 most frequent:
iOMEDICO AG is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
iOMEDICO AG has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
11 of the studies in Carcinoma, Hepatocellular with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05911633Terumo Europe N.V.BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | 2026-11-30 |
| NCT05844046Enrico De ToniSequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients | 2026-12-31 |
| NCT05176483ExelixisStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | 2027-01-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 149 studies in Carcinoma, Hepatocellular with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Hepatocellular Carcinoma (HCC) or Cholangiocarcinoma (CCC) in Germany.
JADE is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of HCC or CCC in Germany. The registry will follow patients for up to three years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.
Health-related quality of life in patients with HCC / CCC will be evaluated for up to three years.
Adult patients with hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCC) starting treatment for early, intermediate or advanced disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signed and dated (IC):
Exclusion criteria:
Patients treated with best supportive care (BSC) only (i.e. no surgery, no radiotherapy, no ablative procedures, no systemic anti-tumoral therapies)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Hepatocellular Carcinoma (HCC)
Other: Physician's choice according to patient's needs.
Patients with Cholangiocarcinoma (CCC)
Other: Physician's choice according to patient's needs.
Routine care as per site standard.
Course of treatment (treatment reality).
Documentation of anamnestic data and therapy sequences.
Time frame: 3 years per patient.
Best Response.
Documentation of response rates per line of treatment.
Time frame: 3 years per patient.
Progression-free survival.
Documentation of progression-free survival per line of treatment.
Time frame: 3 years per patient.
Overall survival.
Documentation of overall survival per line of treatment.
Time frame: 3 years per patient.
Health-related quality of life (Patient-reported outcome, PRO).
EORTC QLQ-C30 core questionnaire \[European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high scale score represents a higher response level: (a) global health status: a high score represents high quality of life, (b) functional scales: a high score represents high/healthy level of functioning, (c) symptom scales/items: a high score represents high level of symptomatology or problems\]
Time frame: 3 years per patient.
Carcinoma Health-related quality of life (Patient-reported outcome, PRO).
EORTC QLQ-HCC18, the hepatocellular carcinoma specific module / EORTC QLQ-BIL21, the cholangiocarcinoma specific module \[European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; Scale 0-100; a high score for scales and single items represents a high level of symptomatology or problems\].
Time frame: 3 years per patient.
Ran from Aug 2020 to primary completion in Oct 2026, 74 months.
Of 49 industry-sponsored observational studies under Carcinoma, Hepatocellular, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's 74 months is above that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.